MedTrace Logo

Cardiac Safety Assessment Study of Picoplatin in Solid Tumors

NCT00710697 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2009-09-24

No results posted yet for this study

Summary

The purpose of this study is to investigate what effects, if any, picoplatin has on the heart rhythm.

Conditions

Interventions

DRUG

Picoplatin

IV 150 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.

Sponsors & Collaborators

  • Poniard Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Robert Earhart, MD, PhD · Poniard Pharmaceuticals

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2009-03-31
Completion
2009-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00710697 on ClinicalTrials.gov